case_images: PMC10710257_01
case_images: Patient at baseline (a-c) and after 16 weeks (d-f) of treatment with risankizumab.
case_images: CCID-16-3503-g0001.jpg
case_images: PMC10710257_01_CCID-16-3503-g0001.jpg
case_images: f0001
case_images: Clinical examination revealed the presence of psoriasis affecting more than 90% of BSA, with a Psoriasis Area Severity Index (PASI) of 37 (Figure 1a-c). After 16 weeks of treatment, a complete resolution of psoriasis (PASI 100) was observed, with a significant improvement in patient's quality of life (Figure 1d-f).